Southcoast Medical was created in order to help patients in Georgia and South Carolina find relief from arthritis and spine pain. Our goal is to help patients regain the active lifestyles they desire, without pain, and without surgery!
Southcoast is owned and staffed by board certified physicians with years of experience in treating spine and joint problems. We offer many Medicare covered treatment options, but our physicians have all had training in Regenerative Medicine and maintain a commitment of continuing education to stay abreast of the most recent advances. We are a Bluetail affiliate, a group with over 50,000 bone marrow procedures done.
The bottom line is that we treat patients the way we would want to be treated. We work hard to find the most simple, easiest option, whether that be medications, simple joint injections, or cellular therapy.
Bluetail Medical Group (BMG) has been practicing Orthopedic Regenerative Medicine since 2004. In fact, the term “Regenerative Orthopedics” had not even been coined when our doctors started using Platelet Rich Plasma. Treatment protocols and pathways were initially based on using early clinical outcomes data and anecdotal evidence. A new field of medicine cannot use an evidence-based approach when no evidence yet exists!
As we expanded our cellular therapy offerings it became imperative that Bluetail collect outcomes data to ensure safety and efficacy. We began using a data collection system that was engineered for Orthopedic Surgeons since one did not exist at that time for Orthopedic Regenerative Medicine. BMG has been formally collecting outcomes data for over 10 years. We use this data to define our success rates with various orthopedic diseases and injuries based on age, sex etc.
As of June 2021, the FDA has put into place a very strict but appropriate regulatory framework for all Regenerative Medicine Clinics. The regulators within the FDA, as well as other parties invested in the non-bio-cellular space, are mandating higher quality studies to be in place to practice Regenerative Medicine. These include Regenerative Medicine Specific Clinical Outcomes Databases, cell counts on cellular therapies, additional safety measures, and many other items. All providers in this space must work within the updated FDA framework or they will be cited. If not eventually compliant, these facilities will be closed permanently.
The great news is that BMG, in conjunction with CRRI, has been working behind the scenes to emerge as the standard for an Orthopedic Regenerative Medicine practice under the new FDA Regulatory Framework. BMG, with CRRI, began regular meetings with the FDA in 2019 when the latter announced the planned updates to their regulation of cellular therapies. We understood that without collaboration with this government agency we would not be able to successfully continue to offer our alternative therapeutics. Through many hours of consultation with the FDA we have secured an IDE (#27960) with the FDA for the use of Bone Marrow in Knee Osteoarthritis. We are using this initial IDE to build upon for other orthopedic diseases.
Southcoast Medical, as part of Bluetail, will continue to grow the dynamic field of Orthopedic Regenerative Medicine in a safe and efficacious manner with guidance from the FDA. Our goals are to offer safe and effective options that we would use, were we the patient, and to set the standard for clinical application of ortho-biologics in the United States.